Garden State Investment Advisory Services LLC Takes Position in I-Mab (NASDAQ:IMAB)

Garden State Investment Advisory Services LLC purchased a new stake in shares of I-Mab (NASDAQ:IMAB) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 144,000 shares of the company’s stock, valued at approximately $179,000.

Separately, Caligan Partners LP raised its holdings in shares of I-Mab by 3.7% during the third quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock valued at $4,339,000 after buying an additional 124,539 shares during the last quarter. 38.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of I-Mab in a report on Friday, November 15th.

I-Mab Price Performance

Shares of NASDAQ:IMAB opened at $0.98 on Tuesday. I-Mab has a 12 month low of $0.90 and a 12 month high of $2.54. The stock’s 50 day moving average price is $1.17 and its 200 day moving average price is $1.35.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.